National Institutes of Health Update

Claire Schuster, MPH
National Institute of Allergy and Infectious Diseases
National Institutes of Health

September 2023

NIAID Updates

NIH selects Dr. Jeanne Marrazzo as director of the National Institute of Allergy and Infectious Diseases

Lawrence A. Tabak, D.D.S., Ph.D., acting director for the National Institutes of Health (NIH), has named Jeanne M. Marrazzo, M.D., as director of NIAID.

NIH Virtual Tour

Explore the NIH Virtual Tour website, where you will find maps and information about the Bethesda, Maryland campus.



Safe and Effective RSV Protein Vaccines

NIAID-funded basic and clinical studies helped establish the fundamental knowledge necessary for the private sector to develop protein vaccines. These vaccines are safe and effective at preventing severe RSV in some target populations.

Influenza Update

Universal Influenza Vaccine Research

U.S. Department of Health and Human Services
NIH News
National Institutes of Health

National Institute of Allergy and Infectious Diseases (NIAID)
http://www.niaid.nih.gov
April 20, 2023

Universal Influenza Candidate Vaccine Performs Well in Phase 1 Trial



Model of the H1ssF nanoparticle
Credit: NIAID

A Widge, *et al*. An Influenza Hemagglutinin Stem Nanoparticle 1 Vaccine Induces Cross Group 1 Neutralizing Antibodies in Healthy Adults. *Science Translational Medicine* (2023 April)

S Andrews, *et al*. An Influenza H1 Hemagglutinin Stem-Only Immunogen Elicits a Broadly Cross-Reactive B Cell Response in Humans. *Science Translational Medicine* (2023 April)

NIH National Institute of Allergy and Infectious Diseases

U.S. Department of Health and Human Services
NIH News
National Institutes of Health

National Institute of Allergy and Infectious Diseases (NIAID)
http://www.niaid.nih.gov
May 15, 2023

Clinical Trial of mRNA Universal Influenza Vaccine Candidate Begins



Colorized transmission electron micrograph showing H1N1 influenza virus particles.

Credit: NIAID

- Phase 1 clinical trial evaluating safety, ability to induce an immune response
- Enrolling up to 50 healthy volunteers ages 18 – 49 years
- The study is being conducted through the NIAID-supported Collaborative Influenza Vaccine Innovation Centers (CIVICs) program

COVID-19 Update

Researching COVID to Enhance Recovery

- NIH opening enrollment for Phase 2 clinical trials that will evaluate potential treatments for long COVID, with additional clinical trials expected in the coming months.
- The trials are designed to evaluate multiple treatments simultaneously.
- Treatments will include drugs, biologics, medical devices and other therapies.
- To learn more about RECOVER trials, visit https://trials.recovercovid.org/



- This workshop aims to bring together multi-disciplinary experts to highlight the latest research on long COVID and chronic inflammation that might be related to the persistent effects of the infection.
- This meeting is open to the public and free to attend, but registration is required to access the event virtually.
- For additional information, please visit https://events.cancer.gov/nih/inflammation-long-covid

U.S. Department of Health and Human Services
NIH News
National Institutes of Health

National Institute of Allergy and Infectious Diseases (NIAID)
http://www.niaid.nih.gov
August 11, 2023

COVID-19 Vaccination and Boosting During Pregnancy Benefits Pregnant People and Newborns

- Results announced from NIAID-supported Multisite Observational Maternal and Infant Study for COVID-19 (MOMI-VAX) study.
- Pregnant people who received COVID-19 vaccines generated antibodies against specific types of SARS-CoV-2, including Omicron.
- Antibodies effectively crossed the placenta, also found in cord blood of vaccinated participants.
- Pregnant participants who received a booster dose had substantially more antibodies against SARS-CoV-2, both in their own blood and in their cord blood.

FM Munoz *et al*. COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn. *Vaccine* (2023 August)

NIH National Institute of Allergy and Infectious Diseases

Next Generation COVID-19 Vaccines

Project NextGen

Led by NIAID and the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Administration for Strategic Preparedness and Response (ASPR), Project NextGen is a coordinated effort where the federal government works with the private sector to advance the pipeline of new, innovative vaccines and therapeutics from labs into clinical trials with the intent to transition to the private sector later stage development and potential U.S. Food and Drug Administration (FDA) authorization, approval, and commercial availability.

How Is NIAID Addressing This Topic?

Through Project NextGen, NIAID aims to accelerate the development of the next generation of COVID-19 vaccines that are ready for clinical evaluation. NIAID plans to leverage existing infrastructure and network sites to implement a structured program evaluating up to 10 next generation COVID-19 vaccines in Phase 1 and Phase 2 clinical trials. The studies will be sponsored by NIAID using common protocols and centralized assays of multiple immune parameters including humoral, cellular, and mucosal responses. These studies will help advance products as well as advance science in the field by evaluating how immunologic parameters correlate with protection from infection and disease.

Thank you